MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Denali Therapeutics Inc. - Common Stock (NQ:DNLI)

18.80 +0.69 (+3.81%)
Streaming Delayed Price Updated: 11:03 AM EDT, May 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Denali Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Why Denali Therapeutics Stock Is Sinking Today ↗
The company reported interim results from a phase 1/2 study of its experimental Hunter syndrome drug. 
Via The Motley Fool
News headline image
48 Stocks Moving In Monday's Mid-Day Session ↗
Gainers Bit Digital, Inc. (NASDAQ: BTBT) gained 38% to $5.83 after the company announced it entered into a second strategic co-mining agreement with Digihost Technology Inc. The... 
Via Benzinga
News headline image
Denali Therapeutics Stock Crashes; Why Investors Are Questioning Its Entire Pipeline ↗
Denali unveiled promising test results in Hunter syndrome, but DNLI stock tanked Monday on broader pipeline viability questions. 
Via Investor's Business Daily
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
Gainers Dynatronics (NASDAQ:DYNT) shares moved upwards by 40.31% to $1.81 during Monday's pre-market session. The company's market cap stands at $31.4 million.... 
Via Benzinga
News headline image
Denali's Brain-Penetrant Enzyme Therapy Shows Durable Effect With CNS Impact In Hunter Syndrome ↗
Denali Therapeutics Inc (NASDAQ: DNLI) announced additional interim data from a Phase 1/2 study evaluating ETV:IDS (DNL310) for the central nervous system (CNS)... 
Via Benzinga
News headline image
Tuesday Talk: Action! ↗
U.S. stock markets started the week in continued action mode. The S&P 500 closed at 4,255, up nearly 8 points, the Dow closed at 34,394, down 85 points and the Nasdaq Composite closed at 14,174, up... 
Via Talk Markets
Topics Stocks
News headline image
Biotechs Ready To Roar ↗
The biggest event last week was the FDA decision to approve Biogen's drug aducanumab, a treatment for Alzheimer's disease. The decision will reverberate across the industry and the healthcare sector... 
Via Talk Markets
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For May 18, 2021 ↗
Upgrades Janney Montgomery Scott upgraded the previous rating for Centerspace (NYSE:CSR) from Neutral to Buy. In the first quarter, Centerspace showed an EPS of $0.95,... 
Via Benzinga
News headline image
Biden's Budget May Boost These 3 Biotechs ↗
It signals a big push toward curing a neurological disease with a massive market. 
Via The Motley Fool
News headline image
Denali-Biogen Parkinson's Disease Candidate Shows Reductions In Biomarkers; Late Study To Begin By 2021 End ↗
Denali Therapeutics Inc (NASDAQ: DNLI) has announced final results from Phase 1 and Phase 1b studies evaluating BIIB122/DNL151 Parkinson's disease. The... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story